KNApSAcK Metabolite C00001408
Metabolite
KNApSAcK Entry
| id | C00001408 |
|---|---|
| Name | Dopamine |
| CAS RN | 51-61-6 |
| Standard InChI | InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2 |
| Standard InChI (Main Layer) | InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2 |
Cluster
| Phytochemical cluster | No. 6 |
|---|---|
| KCF-S cluster | No. 1114 |
Link
ChEMBL
| By standard InChI | CHEMBL59 |
|---|---|
| By standard InChI Main Layer | CHEMBL59 |
KEGG
| By LinkDB | C03758 |
|---|
CTD
| By CAS RN | D004298 |
|---|
Species
Summary
Plant class
| class name | count |
|---|---|
| eudicotyledons | 4 |
| rosids | 2 |
| asterids | 2 |
| Liliopsida | 1 |
Family
| family name | count |
|---|---|
| Fabaceae | 2 |
| Solanaceae | 2 |
| Cactaceae | 1 |
| Nyctaginaceae | 1 |
| Montiaceae | 1 |
| Papaveraceae | 1 |
| Musaceae | 1 |
List (9)
* NCBI
Human Protein / Gene in interaction
69 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P10635 | Cytochrome P450 2D6 | Cytochrome P450 2D6 | CHEMBL59 |
CHEMBL1614110
(1)
CHEMBL1741321
(1)
|
1 / 0 |
| P42345 | Serine/threonine-protein kinase mTOR | Enzyme | CHEMBL59 |
CHEMBL1613805
(1)
CHEMBL1614293
(1)
|
0 / 0 |
| P22310 | UDP-glucuronosyltransferase 1-4 | Enzyme | CHEMBL59 |
CHEMBL1908082
(1)
|
3 / 0 |
| P04637 | Cellular tumor antigen p53 | Transcription Factor | CHEMBL59 |
CHEMBL1613992
(1)
CHEMBL1613995
(1)
|
7 / 44 |
| O15244 | Solute carrier family 22 member 2 | Drug uniporter | CHEMBL59 |
CHEMBL2076309
(1)
CHEMBL2077481
(1)
CHEMBL2075993 (1) CHEMBL2077802 (1) CHEMBL2077803 (1) |
0 / 0 |
| Q9HAW8 | UDP-glucuronosyltransferase 1-10 | Enzyme | CHEMBL59 |
CHEMBL1908087
(1)
|
0 / 0 |
| Q99700 | Ataxin-2 | Unclassified protein | CHEMBL59 |
CHEMBL1794367
(1)
CHEMBL2114784
(1)
|
1 / 1 |
| P21728 | D(1A) dopamine receptor | Dopamine receptor | CHEMBL59 |
CHEMBL668635
(1)
CHEMBL671827
(1)
CHEMBL669035 (1) CHEMBL669037 (1) CHEMBL672961 (1) CHEMBL874062 (1) CHEMBL674898 (1) CHEMBL672093 (1) CHEMBL674241 (1) CHEMBL674247 (1) CHEMBL851657 (1) CHEMBL910610 (1) CHEMBL910611 (1) CHEMBL939919 (1) CHEMBL939921 (1) CHEMBL1053912 (1) CHEMBL1226122 (2) CHEMBL1738091 (1) CHEMBL1737859 (1) CHEMBL1738565 (1) CHEMBL2066739 (1) CHEMBL2114744 (1) CHEMBL2182834 (1) |
0 / 0 |
| Q9Y2D0 | Carbonic anhydrase 5B, mitochondrial | Lyase | CHEMBL59 |
CHEMBL885804
(1)
|
0 / 0 |
| P35218 | Carbonic anhydrase 5A, mitochondrial | Lyase | CHEMBL59 |
CHEMBL885803
(1)
|
0 / 0 |
| P43166 | Carbonic anhydrase 7 | Lyase | CHEMBL59 |
CHEMBL889439
(1)
|
0 / 0 |
| P49286 | Melatonin receptor type 1B | Melatonin receptor | CHEMBL59 |
CHEMBL713140
(1)
|
0 / 1 |
| O15245 | Solute carrier family 22 member 1 | Drug uniporter | CHEMBL59 |
CHEMBL993349
(1)
CHEMBL2076204
(1)
CHEMBL2077753 (1) |
0 / 0 |
| O43704 | Sulfotransferase family cytosolic 1B member 1 | Enzyme | CHEMBL59 |
CHEMBL1743306
(1)
|
0 / 0 |
| P00918 | Carbonic anhydrase 2 | Lyase | CHEMBL59 |
CHEMBL869780
(1)
CHEMBL889437
(1)
CHEMBL887924 (1) CHEMBL932482 (1) CHEMBL970751 (1) CHEMBL953312 (1) CHEMBL1017972 (1) CHEMBL1067709 (1) CHEMBL1106967 (1) CHEMBL2156561 (1) CHEMBL2318049 (1) |
1 / 2 |
| P07550 | Beta-2 adrenergic receptor | Adrenergic receptor | CHEMBL59 |
CHEMBL1058735
(1)
|
0 / 1 |
| Q01959 | Sodium-dependent dopamine transporter | Dopamine | CHEMBL59 |
CHEMBL879564
(1)
CHEMBL670174
(1)
CHEMBL1065537 (1) |
1 / 0 |
| P21918 | D(1B) dopamine receptor | Dopamine receptor | CHEMBL59 |
CHEMBL672961
(1)
CHEMBL874062
(1)
CHEMBL839015 (1) |
1 / 0 |
| P06241 | Tyrosine-protein kinase Fyn | Src | CHEMBL59 |
CHEMBL680969
(1)
|
0 / 0 |
| O95622 | Adenylate cyclase type 5 | Enzyme | CHEMBL59 |
CHEMBL644558
(1)
|
1 / 0 |
| P11712 | Cytochrome P450 2C9 | Cytochrome P450 2C9 | CHEMBL59 |
CHEMBL1741325
(1)
|
0 / 1 |
| P16662 | UDP-glucuronosyltransferase 2B7 | Enzyme | CHEMBL59 |
CHEMBL1908093
(1)
|
0 / 0 |
| Q9HAW7 | UDP-glucuronosyltransferase 1-7 | Enzyme | CHEMBL59 |
CHEMBL1908084
(1)
|
0 / 0 |
| P14416 | D(2) dopamine receptor | Dopamine receptor | CHEMBL59 |
CHEMBL669147
(1)
CHEMBL669148
(1)
CHEMBL669154 (1) CHEMBL672961 (1) CHEMBL874062 (1) CHEMBL671063 (1) CHEMBL673021 (1) CHEMBL673025 (1) CHEMBL671068 (1) CHEMBL671070 (1) CHEMBL671379 (1) CHEMBL672183 (1) CHEMBL672184 (1) CHEMBL672210 (1) CHEMBL672220 (1) CHEMBL672222 (1) CHEMBL670671 (1) CHEMBL671447 (1) CHEMBL672526 (1) CHEMBL672527 (1) CHEMBL672528 (1) CHEMBL670556 (1) CHEMBL670557 (1) CHEMBL670558 (1) CHEMBL872880 (1) CHEMBL876416 (1) CHEMBL849310 (1) CHEMBL851657 (1) CHEMBL844898 (1) CHEMBL911249 (1) CHEMBL910422 (1) CHEMBL910423 (1) CHEMBL926382 (1) CHEMBL939920 (1) CHEMBL939922 (1) CHEMBL971390 (1) CHEMBL995087 (1) CHEMBL995088 (1) CHEMBL1032029 (1) CHEMBL1050541 (1) CHEMBL1066831 (1) CHEMBL1066832 (1) CHEMBL1066833 (1) CHEMBL1065657 (1) CHEMBL1251529 (1) CHEMBL1251532 (1) CHEMBL2066740 (1) CHEMBL2157074 (1) CHEMBL2182830 (1) CHEMBL2182831 (1) CHEMBL2182832 (1) CHEMBL2213376 (1) CHEMBL2346426 (1) CHEMBL2346428 (1) |
2 / 0 |
| P23280 | Carbonic anhydrase 6 | Lyase | CHEMBL59 |
CHEMBL887925
(1)
CHEMBL1067710
(1)
|
0 / 0 |
| Q9ULX7 | Carbonic anhydrase 14 | Lyase | CHEMBL59 |
CHEMBL889441
(1)
|
0 / 0 |
| P00352 | Retinal dehydrogenase 1 | Enzyme | CHEMBL59 |
CHEMBL1614458
(2)
|
0 / 0 |
| O43570 | Carbonic anhydrase 12 | Lyase | CHEMBL59 |
CHEMBL932484
(1)
|
1 / 2 |
| Q16665 | Hypoxia-inducible factor 1-alpha | Transcription Factor | CHEMBL59 |
CHEMBL1614456
(1)
CHEMBL1613803
(1)
|
0 / 0 |
| P39748 | Flap endonuclease 1 | Enzyme | CHEMBL59 |
CHEMBL1613922
(1)
CHEMBL1794486
(2)
|
0 / 0 |
| P50225 | Sulfotransferase 1A1 | Enzyme | CHEMBL59 |
CHEMBL1743314
(1)
|
0 / 0 |
| P54855 | UDP-glucuronosyltransferase 2B15 | Enzyme | CHEMBL59 |
CHEMBL1908090
(1)
|
0 / 0 |
| P08913 | Alpha-2A adrenergic receptor | Adrenergic receptor | CHEMBL59 |
CHEMBL816956
(1)
CHEMBL1228587
(1)
|
0 / 0 |
| P21917 | D(4) dopamine receptor | Dopamine receptor | CHEMBL59 |
CHEMBL672961
(1)
CHEMBL874062
(1)
CHEMBL675192 (1) CHEMBL670989 (1) CHEMBL670990 (1) CHEMBL670991 (1) CHEMBL872781 (1) CHEMBL673648 (1) CHEMBL676181 (1) CHEMBL849310 (1) CHEMBL839607 (1) CHEMBL912415 (1) CHEMBL912416 (1) CHEMBL911046 (1) CHEMBL910419 (1) CHEMBL995090 (1) |
0 / 0 |
| P35462 | D(3) dopamine receptor | Dopamine receptor | CHEMBL59 |
CHEMBL672961
(1)
CHEMBL874062
(1)
CHEMBL674995 (1) CHEMBL879553 (1) CHEMBL674996 (1) CHEMBL673441 (1) CHEMBL674410 (1) CHEMBL679220 (1) CHEMBL679221 (1) CHEMBL926384 (1) CHEMBL971392 (1) CHEMBL995089 (1) CHEMBL981820 (1) CHEMBL1032031 (1) CHEMBL1050543 (1) CHEMBL1065658 (1) CHEMBL1251530 (1) CHEMBL1251533 (1) CHEMBL2066741 (1) CHEMBL2157076 (1) CHEMBL2182827 (1) CHEMBL2182828 (1) CHEMBL2182833 (1) CHEMBL2212937 (1) CHEMBL2346423 (1) |
1 / 0 |
| P00915 | Carbonic anhydrase 1 | Lyase | CHEMBL59 |
CHEMBL869779
(1)
CHEMBL889435
(1)
CHEMBL887923 (1) CHEMBL932481 (1) CHEMBL970750 (1) CHEMBL965608 (1) CHEMBL1067708 (1) CHEMBL2156560 (1) CHEMBL2318048 (1) |
0 / 0 |
| P50224 | Sulfotransferase 1A3/1A4 | Enzyme | CHEMBL59 |
CHEMBL1743305
(1)
|
0 / 0 |
| P14679 | Tyrosinase | Oxidoreductase | CHEMBL59 |
CHEMBL870666
(1)
|
4 / 2 |
| P31645 | Sodium-dependent serotonin transporter | Serotonin | CHEMBL59 |
CHEMBL875081
(1)
CHEMBL805347
(1)
|
2 / 0 |
| P48039 | Melatonin receptor type 1A | Melatonin receptor | CHEMBL59 |
CHEMBL715947
(1)
|
0 / 0 |
| P28482 | Mitogen-activated protein kinase 1 | Erk | CHEMBL59 |
CHEMBL1614521
(1)
|
0 / 0 |
| P05177 | Cytochrome P450 1A2 | Cytochrome P450 1A2 | CHEMBL59 |
CHEMBL1741322
(1)
|
0 / 0 |
| Q16790 | Carbonic anhydrase 9 | Lyase | CHEMBL59 |
CHEMBL932483
(1)
|
0 / 1 |
| Q16853 | Membrane primary amine oxidase | Enzyme | CHEMBL59 |
CHEMBL853855
(1)
|
0 / 0 |
| Q99714 | 3-hydroxyacyl-CoA dehydrogenase type-2 | Enzyme | CHEMBL59 |
CHEMBL1613910
(2)
CHEMBL1614227
(1)
|
3 / 3 |
| P08588 | Beta-1 adrenergic receptor | Adrenergic receptor | CHEMBL59 |
CHEMBL651256
(1)
|
1 / 0 |
| P16050 | Arachidonate 15-lipoxygenase | Enzyme | CHEMBL59 |
CHEMBL1614240
(1)
|
0 / 0 |
| P33261 | Cytochrome P450 2C19 | Cytochrome P450 2C19 | CHEMBL59 |
CHEMBL1741323
(1)
|
1 / 1 |
| P08684 | Cytochrome P450 3A4 | Cytochrome P450 3A4 | CHEMBL59 |
CHEMBL1741324
(1)
|
0 / 1 |
| Q9UNA4 | DNA polymerase iota | Enzyme | CHEMBL59 |
CHEMBL1794483
(1)
|
0 / 0 |
| P27695 | DNA-(apurinic or apyrimidinic site) lyase | Enzyme | CHEMBL59 |
CHEMBL1614466
(1)
CHEMBL1614211
(2)
|
0 / 0 |
| P22309 | UDP-glucuronosyltransferase 1-1 | Enzyme | CHEMBL59 |
CHEMBL1908080
(1)
|
5 / 1 |
| P10636 | Microtubule-associated protein tau | Unclassified protein | CHEMBL59 |
CHEMBL1614421
(2)
|
4 / 3 |
| Q99549 | M-phase phosphoprotein 8 | Unclassified protein | CHEMBL59 |
CHEMBL1738402
(1)
|
0 / 0 |
| P23975 | Sodium-dependent noradrenaline transporter | Norepinephrine | CHEMBL59 |
CHEMBL751147
(1)
CHEMBL751372
(1)
|
1 / 1 |
| P07451 | Carbonic anhydrase 3 | Lyase | CHEMBL59 |
CHEMBL970752
(1)
CHEMBL953319
(1)
|
0 / 0 |
| P22748 | Carbonic anhydrase 4 | Lyase | CHEMBL59 |
CHEMBL970753
(1)
CHEMBL1008327
(1)
|
1 / 1 |
| Q9UBT6 | DNA polymerase kappa | Enzyme | CHEMBL59 |
CHEMBL1794536
(3)
|
0 / 0 |
| B2RXH2 | Lysine-specific demethylase 4E | Enzyme | CHEMBL59 |
CHEMBL1613914
(1)
|
0 / 0 |
| P46063 | ATP-dependent DNA helicase Q1 | Enzyme | CHEMBL59 |
CHEMBL1613829
(2)
CHEMBL1613928
(1)
|
0 / 0 |
| P40225 | Thrombopoietin | Unclassified protein | CHEMBL59 |
CHEMBL1614086
(1)
CHEMBL1614034
(1)
|
1 / 1 |
| Q96KQ7 | Histone-lysine N-methyltransferase EHMT2 | Enzyme | CHEMBL59 |
CHEMBL1738442
(1)
|
0 / 0 |
| Q9NUW8 | Tyrosyl-DNA phosphodiesterase 1 | Enzyme | CHEMBL59 |
CHEMBL1614364
(2)
|
1 / 1 |
| P25100 | Alpha-1D adrenergic receptor | Adrenergic receptor | CHEMBL59 |
CHEMBL859456
(1)
CHEMBL648706
(1)
|
0 / 0 |
| P35368 | Alpha-1B adrenergic receptor | Adrenergic receptor | CHEMBL59 |
CHEMBL859456
(1)
CHEMBL648706
(1)
|
0 / 0 |
| P35348 | Alpha-1A adrenergic receptor | Adrenergic receptor | CHEMBL59 |
CHEMBL859456
(1)
CHEMBL648706
(1)
|
0 / 0 |
| P18089 | Alpha-2B adrenergic receptor | Adrenergic receptor | CHEMBL59 |
CHEMBL816956
(1)
|
0 / 0 |
| P18825 | Alpha-2C adrenergic receptor | Adrenergic receptor | CHEMBL59 |
CHEMBL816956
(1)
|
0 / 0 |
| O94925 | Glutaminase kidney isoform, mitochondrial | Enzyme | CHEMBL59 |
CHEMBL2114738
(1)
|
0 / 0 |
CTD interaction (172)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| D004298 | 183 |
AGT
ANHU SERPINA8 |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Clozapine inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]] |
decreases reaction
/ increases reaction / increases secretion |
protein |
11549694
|
| D004298 | 183 |
AGT
ANHU SERPINA8 |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]] |
increases reaction
/ increases secretion |
protein |
11549694
|
| D004298 | 183 |
AGT
ANHU SERPINA8 |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone] |
increases reaction
/ increases secretion |
protein |
11549694
|
| D004298 | 183 |
AGT
ANHU SERPINA8 |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Raclopride inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]] |
decreases reaction
/ increases reaction / increases secretion |
protein |
11549694
|
| D004298 | 183 |
AGT
ANHU SERPINA8 |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]] |
increases reaction
/ increases secretion |
protein |
11549694
|
| D004298 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | Dopamine results in decreased expression of BAX protein |
decreases expression
|
protein |
19410601
|
| D004298 | 27113 |
BBC3
JFY-1 JFY1 PUMA |
BCL2 binding component 3 | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA |
increases expression
|
mRNA |
19410601
|
| D004298 | 27113 |
BBC3
JFY-1 JFY1 PUMA |
BCL2 binding component 3 | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein |
increases expression
|
protein |
19410601
|
| D004298 | 596 |
BCL2
Bcl-2 PPP1R50 |
B-cell CLL/lymphoma 2 | Dopamine results in decreased expression of BCL2 protein |
decreases expression
|
protein |
17603292
|
| D004298 | 596 |
BCL2
Bcl-2 PPP1R50 |
B-cell CLL/lymphoma 2 | resveratrol inhibits the reaction [Dopamine results in decreased expression of BCL2 protein] |
decreases expression
/ decreases reaction |
protein |
17603292
|
| D004298 | 664 |
BNIP3
NIP3 |
BCL2/adenovirus E1B 19kDa interacting protein 3 | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA |
increases expression
|
mRNA |
19410601
|
| D004298 | 664 |
BNIP3
NIP3 |
BCL2/adenovirus E1B 19kDa interacting protein 3 | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein |
increases expression
|
protein |
19410601
|
| D004298 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
17136323
|
| D004298 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Dopamine results in increased activity of and results in increased cleavage of CASP3 protein |
increases activity
/ increases cleavage |
protein |
17136323
|
| D004298 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Dopamine results in increased activity of CASP3 protein |
increases activity
|
protein |
19410601
|
| D004298 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Dopamine results in increased cleavage of and results in increased activity of CASP3 protein |
increases activity
/ increases cleavage |
protein |
17603292
|
| D004298 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Dopamine results in increased cleavage of CASP3 protein |
increases cleavage
|
protein |
15198987
|
| D004298 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | PARK2 protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
protein |
15198987
|
| D004298 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | resveratrol inhibits the reaction [Dopamine results in increased cleavage of and results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
17603292
|
| D004298 | 840 |
CASP7
CASP-7 CMH-1 ICE-LAP3 LICE2 MCH3 |
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) | Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP7 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
17136323
|
| D004298 | 840 |
CASP7
CASP-7 CMH-1 ICE-LAP3 LICE2 MCH3 |
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) | Dopamine results in increased activity of and results in increased cleavage of CASP7 protein |
increases activity
/ increases cleavage |
protein |
17136323
|
| D004298 | 840 |
CASP7
CASP-7 CMH-1 ICE-LAP3 LICE2 MCH3 |
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) | Dopamine results in increased activity of CASP7 protein |
increases activity
|
protein |
19410601
|
| D004298 | 847 |
CAT
|
catalase (EC:1.11.1.6) | CAT protein inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased abundance of Dopamine] |
decreases abundance
/ decreases reaction |
protein |
11435997
|
| D004298 | 1312 |
COMT
|
catechol-O-methyltransferase (EC:2.1.1.6) | 3,4-methylenedioxyethamphetamine inhibits the reaction [COMT protein results in increased methylation of Dopamine] |
decreases reaction
/ increases methylation |
protein |
19462939
|
| D004298 | 1312 |
COMT
|
catechol-O-methyltransferase (EC:2.1.1.6) | COMT protein results in increased methylation of Dopamine |
increases methylation
|
protein |
11160877
|
| D004298 | 1312 |
COMT
|
catechol-O-methyltransferase (EC:2.1.1.6) | [entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine |
decreases activity
/ increases abundance |
protein |
12898346
|
| D004298 | 1312 |
COMT
|
catechol-O-methyltransferase (EC:2.1.1.6) | N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine inhibits the reaction [COMT protein results in increased methylation of Dopamine] |
decreases reaction
/ increases methylation |
protein |
19462939
|
| D004298 | 1312 |
COMT
|
catechol-O-methyltransferase (EC:2.1.1.6) | [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine |
decreases activity
/ increases abundance |
protein |
7566641
11248589 12898346 |
| D004298 | 1543 |
CYP1A1
AHH AHRR CP11 CYP1 P1-450 P450-C P450DX |
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | Dopamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
decreases reaction
/ increases activity |
protein |
18493746
|
| D004298 | 1565 |
CYP2D6
CPD6 CYP2D CYP2D7AP CYP2D7BP CYP2D7P2 CYP2D8P2 CYP2DL1 CYPIID6 P450-DB1 P450C2D P450DB1 |
cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | Dopamine results in decreased activity of CYP2D6 protein |
decreases activity
|
protein |
18420780
|
| D004298 | 1576 |
CYP3A4
CP33 CP34 CYP3A CYP3A3 CYPIIIA3 CYPIIIA4 HLP NF-25 P450C3 P450PCN1 |
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | Dopamine results in decreased activity of CYP3A4 protein |
decreases activity
|
protein |
18420780
|
| D004298 | 1812 |
DRD1
DADR DRD1A |
dopamine receptor D1 | Dopamine affects the localization of DRD1 protein |
affects localization
|
protein |
15985612
|
| D004298 | 1812 |
DRD1
DADR DRD1A |
dopamine receptor D1 | Dopamine binds to and results in increased activity of DRD1 protein |
affects binding
/ increases activity |
protein |
15985612
|
| D004298 | 1812 |
DRD1
DADR DRD1A |
dopamine receptor D1 | SCH 23390 inhibits the reaction [Dopamine affects the localization of DRD1 protein] |
affects localization
/ decreases reaction |
protein |
15985612
|
| D004298 | 1812 |
DRD1
DADR DRD1A |
dopamine receptor D1 | SCH 23390 inhibits the reaction [Dopamine results in increased activity of DRD1 protein] |
decreases reaction
/ increases activity |
protein |
15985612
|
| D004298 | 1813 |
DRD2
D2DR D2R |
dopamine receptor D2 | [Dopamine co-treated with Raclopride] promotes the reaction [Dopamine binds to DRD2 protein] |
affects binding
/ affects cotreatment / increases reaction |
protein |
19439595
|
| D004298 | 2152 |
F3
CD142 TF TFA |
coagulation factor III (thromboplastin, tissue factor) | Dopamine promotes the reaction [TNF protein results in increased expression of F3 mRNA] |
increases expression
/ increases reaction |
mRNA |
20118172
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
mRNA |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
mRNA |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA |
affects cotreatment
/ increases expression |
mRNA |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein |
affects cotreatment
/ increases expression |
protein |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
mRNA |
12112414
|
| D004298 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 2668 |
GDNF
ATF1 ATF2 HFB1-GDNF HSCR3 |
glial cell derived neurotrophic factor | GDNF protein inhibits the reaction [Oxidopamine results in decreased secretion of Dopamine] |
decreases reaction
/ decreases secretion |
protein |
12213621
|
| D004298 | 2938 |
GSTA1
GST2 GSTA1-1 GTH1 |
glutathione S-transferase alpha 1 (EC:2.5.1.18) | Dopamine analog results in decreased activity of GSTA1 protein |
decreases activity
|
protein |
8131222
|
| D004298 | 2944 |
GSTM1
GST1 GSTM1-1 GSTM1a-1a GSTM1b-1b GTH4 GTM1 H-B MU MU-1 |
glutathione S-transferase mu 1 (EC:2.5.1.18) | Dopamine analog results in decreased activity of GSTM1 protein |
decreases activity
|
protein |
8131222
|
| D004298 | 2950 |
GSTP1
DFN7 FAEES3 GST3 GSTP PI |
glutathione S-transferase pi 1 (EC:2.5.1.18) | Dopamine analog results in decreased activity of GSTP1 protein |
decreases activity
|
protein |
8131222
|
| D004298 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Acetylcysteine inhibits the reaction [Dopamine results in increased expression of HIF1A protein] |
decreases reaction
/ increases expression |
protein |
19410601
|
| D004298 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Dopamine results in increased expression of HIF1A protein |
increases expression
|
protein |
19410601
|
| D004298 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein |
increases expression
/ increases phosphorylation |
protein |
19410601
|
| D004298 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA |
increases expression
|
protein |
19410601
|
| D004298 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein |
increases expression
|
protein |
19410601
|
| D004298 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA |
increases expression
|
protein |
19410601
|
| D004298 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein |
increases expression
|
protein |
19410601
|
| D004298 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein |
increases expression
|
protein |
19410601
|
| D004298 | 3162 |
HMOX1
HMOX1D HO-1 HSP32 bK286B10 |
heme oxygenase (decycling) 1 (EC:1.14.99.3) | HMOX1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased abundance of Dopamine] |
decreases abundance
/ decreases reaction |
protein |
18799798
|
| D004298 | 3359 |
HTR3A
5-HT-3 5-HT3A 5-HT3R 5HT3R HTR3 |
5-hydroxytryptamine (serotonin) receptor 3A, ionotropic | Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3A protein] |
affects binding
/ increases activity |
protein |
17360702
|
| D004298 | 3359 |
HTR3A
5-HT-3 5-HT3A 5-HT3R 5HT3R HTR3 |
5-hydroxytryptamine (serotonin) receptor 3A, ionotropic | Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein] |
affects binding
/ increases activity |
protein |
17360702
|
| D004298 | 9177 |
HTR3B
5-HT3B |
5-hydroxytryptamine (serotonin) receptor 3B, ionotropic | Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein] |
affects binding
/ increases activity |
protein |
17360702
|
| D004298 | 3630 |
INS
IDDM2 ILPR IRDN MODY10 |
insulin | Dopamine promotes the reaction [Metoclopramide results in increased expression of INS protein] |
increases expression
/ increases reaction |
protein |
18645345
|
| D004298 | 3630 |
INS
IDDM2 ILPR IRDN MODY10 |
insulin | Dopamine results in increased expression of INS protein |
increases expression
|
protein |
18645345
|
| D004298 | 3630 |
INS
IDDM2 ILPR IRDN MODY10 |
insulin | Dopamine results in increased secretion of INS protein |
increases secretion
|
protein |
18645345
|
| D004298 | 3725 |
JUN
AP-1 AP1 c-Jun |
jun proto-oncogene | Dopamine results in increased phosphorylation of JUN protein |
increases phosphorylation
|
protein |
15198987
|
| D004298 | 3725 |
JUN
AP-1 AP1 c-Jun |
jun proto-oncogene | PARK2 protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein] |
decreases reaction
/ increases phosphorylation |
protein |
15198987
|
| D004298 | 5594 |
MAPK1
ERK ERK2 ERT1 MAPK2 P42MAPK PRKM1 PRKM2 p38 p40 p41 p41mapk |
mitogen-activated protein kinase 1 (EC:2.7.11.24) | Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein |
increases activity
/ increases phosphorylation |
protein |
18977218
|
| D004298 | 5594 |
MAPK1
ERK ERK2 ERT1 MAPK2 P42MAPK PRKM1 PRKM2 p38 p40 p41 p41mapk |
mitogen-activated protein kinase 1 (EC:2.7.11.24) | RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
affects reaction
/ increases activity / increases phosphorylation |
protein |
18977218
|
| D004298 | 5595 |
MAPK3
ERK-1 ERK1 ERT2 HS44KDAP HUMKER1A P44ERK1 P44MAPK PRKM3 p44-ERK1 p44-MAPK |
mitogen-activated protein kinase 3 (EC:2.7.11.24) | Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein |
increases activity
/ increases phosphorylation |
protein |
18977218
|
| D004298 | 5595 |
MAPK3
ERK-1 ERK1 ERT2 HS44KDAP HUMKER1A P44ERK1 P44MAPK PRKM3 p44-ERK1 p44-MAPK |
mitogen-activated protein kinase 3 (EC:2.7.11.24) | RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
affects reaction
/ increases activity / increases phosphorylation |
protein |
18977218
|
| D004298 | 4137 |
MAPT
DDPAC FTDP-17 MAPTL MSTD MTBT1 MTBT2 PPND TAU |
microtubule-associated protein tau | Dopamine metabolite promotes the reaction [MAPT protein binds to MAPT protein] |
affects binding
/ increases reaction |
protein |
16180106
|
| D004298 | 4137 |
MAPT
DDPAC FTDP-17 MAPTL MSTD MTBT1 MTBT2 PPND TAU |
microtubule-associated protein tau | Dopamine promotes the reaction [MAPT protein binds to MAPT protein] |
affects binding
/ increases reaction |
protein |
16180106
|
| D004298 | 2475 |
MTOR
FRAP FRAP1 FRAP2 RAFT1 RAPT1 |
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) | Dopamine results in decreased phosphorylation of MTOR protein |
decreases phosphorylation
|
protein |
19410601
|
| D004298 | 4548 |
MTR
HMAG MS cblG |
5-methyltetrahydrofolate-homocysteine methyltransferase (EC:2.1.1.13) | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein] |
decreases reaction
/ increases activity |
protein |
14745455
|
| D004298 | 4548 |
MTR
HMAG MS cblG |
5-methyltetrahydrofolate-homocysteine methyltransferase (EC:2.1.1.13) | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein] |
decreases reaction
/ increases activity |
protein |
14745455
|
| D004298 | 4548 |
MTR
HMAG MS cblG |
5-methyltetrahydrofolate-homocysteine methyltransferase (EC:2.1.1.13) | Dopamine results in increased activity of MTR protein |
increases activity
|
protein |
14745455
|
| D004298 | 4548 |
MTR
HMAG MS cblG |
5-methyltetrahydrofolate-homocysteine methyltransferase (EC:2.1.1.13) | Ethanol promotes the reaction [Dopamine results in increased activity of MTR protein] |
increases activity
/ increases reaction |
protein |
14745455
|
| D004298 | 4548 |
MTR
HMAG MS cblG |
5-methyltetrahydrofolate-homocysteine methyltransferase (EC:2.1.1.13) | wortmannin inhibits the reaction [Dopamine results in increased activity of MTR protein] |
decreases reaction
/ increases activity |
protein |
14745455
|
| D004298 | 5071 |
PARK2
AR-JP LPRS2 PDJ PRKN |
parkin RBR E3 ubiquitin protein ligase | Dopamine results in increased expression of PARK2 mRNA |
increases expression
|
mRNA |
16987221
|
| D004298 | 5071 |
PARK2
AR-JP LPRS2 PDJ PRKN |
parkin RBR E3 ubiquitin protein ligase | PARK2 protein inhibits the reaction [Dopamine results in increased abundance of Reactive Oxygen Species] |
decreases reaction
/ increases abundance |
protein |
15198987
|
| D004298 | 5071 |
PARK2
AR-JP LPRS2 PDJ PRKN |
parkin RBR E3 ubiquitin protein ligase | PARK2 protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
protein |
15198987
|
| D004298 | 5071 |
PARK2
AR-JP LPRS2 PDJ PRKN |
parkin RBR E3 ubiquitin protein ligase | PARK2 protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
15198987
|
| D004298 | 5071 |
PARK2
AR-JP LPRS2 PDJ PRKN |
parkin RBR E3 ubiquitin protein ligase | PARK2 protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein] |
decreases reaction
/ increases phosphorylation |
protein |
15198987
|
| D004298 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | Dopamine results in increased cleavage of PARP1 protein |
increases cleavage
|
protein |
15198987
17603292 19410601 |
| D004298 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | PARK2 protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
15198987
|
| D004298 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | resveratrol inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
17603292
|
| D004298 | 5617 |
PRL
|
prolactin | Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein] |
decreases expression
/ decreases reaction |
protein |
8532072
|
| D004298 | 5617 |
PRL
|
prolactin | Dopamine results in decreased expression of PRL protein |
decreases expression
|
protein |
8532072
|
| D004298 | 5998 |
RGS3
C2PA RGP3 |
regulator of G-protein signaling 3 | RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
affects reaction
/ increases activity / increases phosphorylation |
protein |
18977218
|
| D004298 | 5998 |
RGS3
C2PA RGP3 |
regulator of G-protein signaling 3 | RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
affects reaction
/ increases activity / increases phosphorylation |
protein |
18977218
|
| D004298 | 6198 |
RPS6KB1
PS6K S6K S6K-beta-1 S6K1 STK14A p70_S6KA p70(S6K)-alpha p70-S6K p70-alpha |
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) | Dopamine results in decreased phosphorylation of RPS6KB1 protein |
decreases phosphorylation
|
protein |
19410601
|
| D004298 | 6343 |
SCT
|
secretin | SCT protein results in increased metabolism of Dopamine |
increases metabolic processing
|
protein |
16168596
|
| D004298 | 6570 |
SLC18A1
CGAT VAT1 VMAT1 |
solute carrier family 18 (vesicular monoamine transporter), member 1 | Dopamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin] |
decreases reaction
/ increases uptake |
protein |
8245983
|
| D004298 | 6571 |
SLC18A2
SVAT SVMT VAT2 VMAT2 |
solute carrier family 18 (vesicular monoamine transporter), member 2 | Dopamine binds to SLC18A2 protein |
affects binding
|
protein |
7912402
|
| D004298 | 6571 |
SLC18A2
SVAT SVMT VAT2 VMAT2 |
solute carrier family 18 (vesicular monoamine transporter), member 2 | Dopamine results in decreased activity of SLC18A2 protein |
decreases activity
|
protein |
15475732
|
| D004298 | 6571 |
SLC18A2
SVAT SVMT VAT2 VMAT2 |
solute carrier family 18 (vesicular monoamine transporter), member 2 | Heptachlor Epoxide inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
10499361
|
| D004298 | 85413 |
SLC22A16
CT2 FLIPT2 OAT6 OCT6 OKB1 dJ261K5.1 |
solute carrier family 22 (organic cation/carnitine transporter), member 16 | Dopamine inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] |
decreases reaction
/ increases uptake |
protein |
15963465
|
| D004298 | 9016 |
SLC25A14
BMCP1 UCP5 |
solute carrier family 25 (mitochondrial carrier, brain), member 14 | Dactinomycin inhibits the reaction [Dopamine results in increased expression of SLC25A14 mRNA] |
decreases reaction
/ increases expression |
mRNA |
20600837
|
| D004298 | 9016 |
SLC25A14
BMCP1 UCP5 |
solute carrier family 25 (mitochondrial carrier, brain), member 14 | Dopamine results in increased expression of SLC25A14 mRNA |
increases expression
|
mRNA |
20600837
|
| D004298 | 9016 |
SLC25A14
BMCP1 UCP5 |
solute carrier family 25 (mitochondrial carrier, brain), member 14 | SLC25A14 protein inhibits the reaction [Dopamine results in increased abundance of Superoxides] |
decreases reaction
/ increases abundance |
protein |
20600837
|
| D004298 | 9016 |
SLC25A14
BMCP1 UCP5 |
solute carrier family 25 (mitochondrial carrier, brain), member 14 | SLC25A14 protein results in decreased susceptibility to Dopamine |
decreases response to substance
|
protein |
20600837
|
| D004298 | 6530 |
SLC6A2
NAT1 NET NET1 SLC6A5 |
solute carrier family 6 (neurotransmitter transporter), member 2 | Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 6530 |
SLC6A2
NAT1 NET NET1 SLC6A5 |
solute carrier family 6 (neurotransmitter transporter), member 2 | indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 6530 |
SLC6A2
NAT1 NET NET1 SLC6A5 |
solute carrier family 6 (neurotransmitter transporter), member 2 | SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] |
increases activity
/ increases reaction |
protein |
17234900
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Amphetamine inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine] |
decreases reaction
/ increases export |
protein |
18614672
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Benztropine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
17250655
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Butyrates inhibits the reaction [Cocaine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]] |
decreases reaction
/ increases uptake |
protein |
17250655
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Butyrates inhibits the reaction [Mazindol inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]] |
decreases reaction
/ increases uptake |
protein |
17250655
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Cocaine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
17250655
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | decamethrin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
16005927
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Dopamine affects the localization of SLC6A3 protein |
affects localization
|
protein |
20875051
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA |
affects cotreatment
/ increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein |
affects cotreatment
/ increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Mazindol inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
17250655
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Melitten inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
20969853
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] |
affects cotreatment
/ decreases reaction / increases expression |
protein |
12112414
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Methylphenidate inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine] |
decreases reaction
/ increases export |
protein |
18614672
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Nomifensine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
20875051
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Permethrin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
16005927
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | SLC6A3 protein mutant form results in increased export of Dopamine |
increases export
|
protein |
18614672
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] |
increases activity
/ increases reaction |
protein |
17234900
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | SLC6A3 protein results in increased transport of Dopamine |
increases transport
|
protein |
11707631
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | SLC6A3 protein results in increased uptake of Dopamine |
increases uptake
|
protein |
16005927
17250655 20875051 20969853 |
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Sulpiride inhibits the reaction [Dopamine affects the localization of SLC6A3 protein] |
affects localization
/ decreases reaction |
protein |
20875051
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | Sulpiride inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
20875051
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | vanoxerine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
17250655
|
| D004298 | 6531 |
SLC6A3
DAT DAT1 PKDYS |
solute carrier family 6 (neurotransmitter transporter), member 3 | wortmannin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
decreases reaction
/ increases uptake |
protein |
20875051
|
| D004298 | 6532 |
SLC6A4
5-HTT 5-HTTLPR 5HTT HTT OCD1 SERT SERT1 hSERT |
solute carrier family 6 (neurotransmitter transporter), member 4 | Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 6532 |
SLC6A4
5-HTT 5-HTTLPR 5HTT HTT OCD1 SERT SERT1 hSERT |
solute carrier family 6 (neurotransmitter transporter), member 4 | indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 6532 |
SLC6A4
5-HTT 5-HTTLPR 5HTT HTT OCD1 SERT SERT1 hSERT |
solute carrier family 6 (neurotransmitter transporter), member 4 | SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] |
increases activity
/ increases reaction |
protein |
17234900
|
| D004298 | 6622 |
SNCA
NACP PARK1 PARK4 PD1 |
synuclein, alpha (non A4 component of amyloid precursor) | SNCA gene mutant form results in increased susceptibility to Dopamine |
increases response to substance
|
gene |
15234109
|
| D004298 | 6622 |
SNCA
NACP PARK1 PARK4 PD1 |
synuclein, alpha (non A4 component of amyloid precursor) | SNCA protein affects the abundance of Dopamine |
affects abundance
|
protein |
17131421
|
| D004298 | 6817 |
SULT1A1
HAST1/HAST2 P-PST PST ST1A1 ST1A3 STP STP1 TSPST1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 (EC:2.8.2.1) | Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
11181495
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | 2,6-dichloro-4-nitrophenol inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
11425650
15531517 |
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | 3,3'-diiodothyronine inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
15531517
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | Clioquinol inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
21820498
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | daidzein inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
15531517
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | Ethanol inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
14570759
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | Genistein inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
15531517
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | Mefenamic Acid inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
11181495
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | Sodium Chloride inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
11425650
15531517 |
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | SULT1A3 protein results in increased sulfation of Dopamine |
increases sulfation
|
protein |
11181495
14570759 19646966 |
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | Thyroxine inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
15531517
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | Triiodothyronine inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
15531517
|
| D004298 | 6818 |
SULT1A3
HAST HAST3 M-PST ST1A3/ST1A4 ST1A5 STM TL-PST |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) | Triiodothyronine, Reverse inhibits the reaction [SULT1A3 protein results in increased sulfation of Dopamine] |
decreases reaction
/ increases sulfation |
protein |
15531517
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]] |
decreases reaction
/ increases activity / increases reaction |
protein |
17234900
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] |
increases activity
/ increases reaction |
protein |
17234900
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] |
increases activity
/ increases reaction |
protein |
17234900
|
| D004298 | 134864 |
TAAR1
RP11-295F4.9 TA1 TAR1 TRAR1 |
trace amine associated receptor 1 | SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] |
increases activity
/ increases reaction |
protein |
17234900
|
| D004298 | 7054 |
TH
DYT14 DYT5b TYH |
tyrosine hydroxylase (EC:1.14.16.2) | TH protein results in increased chemical synthesis of Dopamine |
increases chemical synthesis
|
protein |
19815691
|
| D004298 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Dopamine promotes the reaction [TNF protein results in increased expression of F3 mRNA] |
increases expression
/ increases reaction |
protein |
20118172
|
| D004298 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | TNF protein inhibits the reaction [Methamphetamine results in decreased uptake of Dopamine] |
decreases reaction
/ decreases uptake |
protein |
14999072
|
| D004298 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | TNF protein inhibits the reaction [Methamphetamine results in increased secretion of Dopamine] |
decreases reaction
/ increases secretion |
protein |
14999072
|
| D004298 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | TNF protein results in increased uptake of Dopamine |
increases uptake
|
protein |
14999072
|
| D004298 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein |
increases expression
/ increases phosphorylation |
protein |
19410601
|
| D004298 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | [Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein |
increases expression
|
protein |
19410601
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (40)
| OMIM | preferred title | UniProt |
|---|---|---|
| #300438 | 17-beta-hydroxysteroid dehydrogenase x deficiency |
Q99714
|
| #202300 | Adrenocortical carcinoma, hereditary; adcc |
P04637
|
| #103470 | Albinism, ocular, with sensorineural deafness |
P14679
|
| #203100 | Albinism, oculocutaneous, type ia; oca1a |
P14679
|
| #606952 | Albinism, oculocutaneous, type ib; oca1b |
P14679
|
| #103780 | Alcohol dependence |
P14416
P31645 |
| #614740 | Basal cell carcinoma, susceptibility to, 7; bcc7 |
P04637
|
| #601816 | Bilirubin, serum level of, quantitative trait locus 1; biliqtl1 |
P22309
|
| #606798 | Blepharospasm, benign essential |
P21918
|
| #218800 | Crigler-najjar syndrome, type i |
P22309
P22310 |
| #606785 | Crigler-najjar syndrome, type ii |
P22309
P22310 |
| #609535 | Drug metabolism, poor, cyp2c19-related |
P33261
|
| #608902 | Drug metabolism, poor, cyp2d6-related |
P10635
|
| #606703 | Dyskinesia, familial, with facial myokymia; fdfm |
O95622
|
| #133239 | Esophageal cancer |
P04637
|
| #600274 | Frontotemporal dementia; ftd |
P10636
|
| #143500 | Gilbert syndrome |
P22309
P22310 |
| #237900 | Hyperbilirubinemia, transient familial neonatal; hblrtfn |
P22309
|
| #143860 | Hyperchlorhidrosis, isolated |
O43570
|
| #151623 | Li-fraumeni syndrome 1; lfs1 |
P04637
|
| #211980 | Lung cancer |
P04637
|
| #300705 | Mental retardation, x-linked 17; mrx17 |
Q99714
|
| #300220 | Mental retardation, x-linked, syndromic 10; mrxs10 |
Q99714
|
| #159900 | Myoclonic dystonia |
P14416
|
| #164230 | Obsessive-compulsive disorder; ocd |
P31645
|
| #604715 | Orthostatic intolerance |
P23975
|
| #259730 | Osteopetrosis, autosomal recessive 3; optb3 |
P00918
|
| #260500 | Papilloma of choroid plexus; cpp |
P04637
|
| #260540 | Parkinson-dementia syndrome |
P10636
|
| #613135 | Parkinsonism-dystonia, infantile; pkdys |
Q01959
|
| #172700 | Pick disease of brain |
P10636
|
| #607276 | Resting heart rate, variation in |
P08588
|
| #600852 | Retinitis pigmentosa 17; rp17 |
P22748
|
| #601800 | Skin/hair/eye pigmentation, variation in, 3; shep3 |
P14679
|
| #183090 | Spinocerebellar ataxia 2; sca2 |
Q99700
|
| #607250 | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 |
Q9NUW8
|
| #275355 | Squamous cell carcinoma, head and neck; hnscc |
P04637
|
| #601104 | Supranuclear palsy, progressive, 1; psnp1 |
P10636
|
| #187950 | Thrombocythemia 1; thcyt1 |
P40225
|
| #190300 | Tremor, hereditary essential, 1; etm1 |
P35462
|
KEGG DISEASE (56)
| KEGG | disease name | UniProt |
|---|---|---|
| H01302 | Hyperchlorhidrosis isolated (HCHLH) |
O43570
(related)
|
| H00021 | Renal cell carcinoma |
O43570
(marker)
P04637 (marker) Q16790 (marker) |
| H00241 | Combined proximal and distal renal tubular acidosis (RTA type 3) |
P00918
(related)
|
| H00436 | Osteopetrosis |
P00918
(related)
|
| H00004 | Chronic myeloid leukemia (CML) |
P04637
(related)
|
| H00005 | Chronic lymphocytic leukemia (CLL) |
P04637
(related)
|
| H00006 | Hairy-cell leukemia |
P04637
(related)
|
| H00008 | Burkitt lymphoma |
P04637
(related)
|
| H00009 | Adult T-cell leukemia |
P04637
(related)
|
| H00010 | Multiple myeloma |
P04637
(related)
|
| H00013 | Small cell lung cancer |
P04637
(related)
|
| H00014 | Non-small cell lung cancer |
P04637
(related)
|
| H00015 | Malignant pleural mesothelioma |
P04637
(related)
|
| H00016 | Oral cancer |
P04637
(related)
P04637 (marker) |
| H00017 | Esophageal cancer |
P04637
(related)
P04637 (marker) |
| H00018 | Gastric cancer |
P04637
(related)
|
| H00019 | Pancreatic cancer |
P04637
(related)
P04637 (marker) |
| H00020 | Colorectal cancer |
P04637
(related)
P04637 (marker) |
| H00022 | Bladder cancer |
P04637
(related)
|
| H00025 | Penile cancer |
P04637
(related)
P04637 (marker) |
| H00026 | Endometrial Cancer |
P04637
(related)
|
| H00027 | Ovarian cancer |
P04637
(related)
|
| H00028 | Choriocarcinoma |
P04637
(related)
|
| H00029 | Vulvar cancer |
P04637
(related)
|
| H00031 | Breast cancer |
P04637
(related)
|
| H00032 | Thyroid cancer |
P04637
(related)
|
| H00033 | Adrenal carcinoma |
P04637
(related)
|
| H00036 | Osteosarcoma |
P04637
(related)
P08684 (marker) |
| H00038 | Malignant melanoma |
P04637
(related)
P14679 (marker) |
| H00039 | Basal cell carcinoma |
P04637
(related)
|
| H00040 | Squamous cell carcinoma |
P04637
(related)
|
| H00041 | Kaposi's sarcoma |
P04637
(related)
|
| H00042 | Glioma |
P04637
(related)
P04637 (marker) |
| H00044 | Cancer of the anal canal |
P04637
(related)
|
| H00046 | Cholangiocarcinoma |
P04637
(related)
|
| H00047 | Gallbladder cancer |
P04637
(related)
|
| H00048 | Hepatocellular carcinoma |
P04637
(related)
|
| H00055 | Laryngeal cancer |
P04637
(related)
P04637 (marker) |
| H00881 | Li-Fraumeni syndrome |
P04637
(related)
|
| H01007 | Choroid plexus papilloma |
P04637
(related)
|
| H00079 | Asthma |
P07550
(related)
|
| H00058 | Amyotrophic lateral sclerosis (ALS) |
P10636
(related)
|
| H00077 | Progressive supranuclear palsy (PSP) |
P10636
(related)
|
| H00078 | Frontotemporal lobar degeneration (FTLD) |
P10636
(related)
|
| H01205 | Coumarin resistance |
P11712
(related)
|
| H00168 | Oculocutaneous albinism (OCA) |
P14679
(related)
|
| H00208 | Hyperbilirubinemia |
P22309
(related)
|
| H00527 | Retinitis pigmentosa (RP) |
P22748
(related)
|
| H01031 | Orthostatic intolerance (OI) |
P23975
(related)
|
| H01171 | Poor drug metabolism (PM) |
P33261
(related)
|
| H00227 | Congenital amegakaryocytic thrombocytopenia (CAMT) |
P40225
(marker)
|
| H00409 | Type II diabetes mellitus |
P49286
(related)
|
| H00063 | Spinocerebellar ataxia (SCA) |
Q99700
(related)
Q9NUW8 (related) |
| H00480 | Non-syndromic X-linked mental retardation |
Q99714
(related)
|
| H00658 | Syndromic X-linked mental retardation |
Q99714
(related)
|
| H00925 | 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency |
Q99714
(related)
|
Diseases related to CTD interactions
52 disease from interactions of metabolites
| MeSH disease | OMIM | compound | disease name | evidence type |
reference
pmid |
|---|---|---|---|---|---|
| D058186 | D004298 | Acute Kidney Injury |
therapeutic
|
1769878
|
|
| D000788 | D004298 | Angina Pectoris, Variant |
marker/mechanism
|
491823
|
|
| D001145 | D004298 | Arrhythmias, Cardiac |
marker/mechanism
|
6195467
7568905 |
|
| D001480 | D004298 | Basal Ganglia Diseases |
marker/mechanism
|
619844
|
|
| D002303 | D004298 | Cardiac Output, Low |
therapeutic
|
10667021
|
|
| D002375 | D004298 | Catalepsy |
marker/mechanism
therapeutic |
7953768
9822156 10984662 |
|
| D002389 | D004298 | Catatonia |
marker/mechanism
|
6540303
|
|
| D002493 | D004298 | Central Nervous System Diseases |
marker/mechanism
|
1810626
15249736 |
|
| D019970 | D004298 | Cocaine-Related Disorders |
marker/mechanism
therapeutic |
9608576
10485969 10804227 11080549 11606653 11750899 12122083 12687000 12807430 16775146 16971900 20053903 |
|
| D004342 | D004298 | Drug Hypersensitivity |
marker/mechanism
|
15090952
|
|
| D062787 | D004298 | Drug Overdose |
therapeutic
|
9711203
11914425 |
|
| D004409 | D004298 | Dyskinesia, Drug-Induced |
marker/mechanism
therapeutic |
189712
2953603 17920284 |
|
| D004417 | D004298 | Dyspnea |
therapeutic
|
15564710
|
|
| D004802 | D004298 | Eosinophilia |
marker/mechanism
|
15090952
|
|
| D006323 | D004298 | Heart Arrest |
therapeutic
|
7762840
|
|
| D006331 | D004298 | Heart Diseases |
therapeutic
|
378019
6542785 |
|
| D006333 | D004298 | Heart Failure |
therapeutic
|
3630900
8091823 |
|
| D006556 | D004298 | Heroin Dependence |
marker/mechanism
|
11750899
|
|
| D006930 | D004298 | Hyperalgesia |
marker/mechanism
|
7881729
10401557 |
|
| D006948 | D004298 | Hyperkinesis |
marker/mechanism
|
9822156
18347339 |
|
| D006973 | D004298 | Hypertension |
marker/mechanism
|
1033105
1574468 2468958 3766759 6690337 10981248 |
|
| D007008 | D004298 | Hypokalemia |
marker/mechanism
|
2471006
|
|
| D018476 | D004298 | Hypokinesia |
marker/mechanism
therapeutic |
2953603
18308296 |
|
| D007022 | D004298 | Hypotension |
marker/mechanism
therapeutic |
637689
1966119 3756030 6498583 6542785 6646141 6740701 6928405 8214766 8580515 10737566 10981248 12064475 15518130 15582773 16188828 16803915 |
|
| D007024 | D004298 | Hypotension, Orthostatic |
therapeutic
|
10369619
|
|
| D007859 | D004298 | Learning Disorders |
marker/mechanism
|
9822156
10984662 |
|
| D008133 | D004298 | Long QT Syndrome |
marker/mechanism
|
11266201
|
|
| D020149 | D004298 | Manganese Poisoning |
marker/mechanism
|
20865164
|
|
| D048629 | D004298 | Micronuclei, Chromosome-Defective |
marker/mechanism
|
20875051
|
|
| D017202 | D004298 | Myocardial Ischemia |
marker/mechanism
|
10051940
|
|
| D009205 | D004298 | Myocarditis |
marker/mechanism
|
15090952
|
|
| D009336 | D004298 | Necrosis |
marker/mechanism
|
18079140
21983523 |
|
| D009410 | D004298 | Nerve Degeneration |
marker/mechanism
|
17136323
19388687 20865164 |
|
| D009422 | D004298 | Nervous System Diseases |
marker/mechanism
|
9427479
9634552 20722968 |
|
| D009846 | D004298 | Oliguria |
therapeutic
|
512416
6646141 |
|
| D010300 | D004298 | Parkinson Disease |
marker/mechanism
|
20085714
|
|
| D020734 | D004298 | Parkinsonian Disorders |
marker/mechanism
|
1275103
|
|
| D010547 | D004298 | Persistent Fetal Circulation Syndrome |
therapeutic
|
6646141
|
|
| D011595 | D004298 | Psychomotor Agitation |
marker/mechanism
|
2962686
|
|
| D012127 | D004298 | Respiratory Distress Syndrome, Newborn |
therapeutic
|
9175527
|
|
| D012640 | D004298 | Seizures |
marker/mechanism
therapeutic |
2622091
7634817 9249254 14559291 15140183 15946324 16771832 18005069 20433896 |
|
| D012769 | D004298 | Shock |
therapeutic
|
10570779
|
|
| D012770 | D004298 | Shock, Cardiogenic |
therapeutic
|
9064946
16143579 20723251 |
|
| D012772 | D004298 | Shock, Septic |
therapeutic
|
3578867
|
|
| D013226 | D004298 | Status Epilepticus |
marker/mechanism
|
15488322
15876489 16563474 |
|
| D013375 | D004298 | Substance Withdrawal Syndrome |
marker/mechanism
|
9608576
15941493 |
|
| D013610 | D004298 | Tachycardia |
marker/mechanism
|
1255483
16143579 17587605 |
|
| D013616 | D004298 | Tachycardia, Sinus |
marker/mechanism
|
19851126
|
|
| D016171 | D004298 | Torsades de Pointes |
marker/mechanism
therapeutic |
6465184
15312873 |
|
| D014202 | D004298 | Tremor |
therapeutic
|
2953603
|
|
| D020301 | D004298 | Vasospasm, Intracranial |
marker/mechanism
|
11481148
|
|
| D018487 | D004298 | Ventricular Dysfunction, Left |
therapeutic
|
16750736
|